Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fiserv

Visa

Powell believes returning to bigger rate hikes could be necessary if data suggests the U.S. economy is heating up again. Is this the correct path to take?

Navigating Volatility: 3 Stocks Worthy of Consideration

KALAMAZOO, Michigan, USA, March 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its CD NXT System, the latest innovation in the company's power tools. This patented technology provides real-time depth measurement as the surgeon drills, allowing for fast, accurate, consistent digital depth measurement across various procedures.

CD NXT power tool system empowers surgeons through real-time depth measurement

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Stryker (SYK) is a Top Growth Stock for the Long-Term

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK), one of the world's leading medical technology companies, today announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from the U.S. Food and Drug Administration. The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries. Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market.

Stryker's Q Guidance System for cranial applications receives FDA clearance

This medical devices company is already up in 2023. Should you buy it?

Should Investors Buy This Dividend Growth Stock?

Haemonetics

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.

3 Medical Products Stocks Navigating Industry Challenges

Ares Capital

Cisco Systems

Medtronic

Altria

Annaly Capital

Rithm Capital Corp

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season.

My Dividend Stock Portfolio: New January Record - 100 Holdings With 26 Buys

Stryker saw volume-driven top-line growth as a result of meaningful acquisition and a favorable demand environment. It continues to improve its product portfolio, making it well positioned to be a relevant player in the industry.

Stryker Has A Slowing FCF Conversion And No Plans Of Share Buyback

Stryker (SYK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Stryker (SYK) a New Buy Stock

Advanced Micro Devices

Amgen

Electronic Arts

FedEx

Peloton

Rivian Automotive

Snap

U.S. stock markets started Feb. 1 with declines on news of the Fed's latest rate hike but ended the day higher following comments from the Fed chair.

US Markets Rally Back on Powell Comments

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs adversely impact margins.

Stryker's (SYK) Q4 Earnings Beat Estimates, Volume Improves

Stryker Corporation (NYSE:SYK ) Q4 2022 Earnings Conference Call January 31, 2023 4:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Vijay Kumar - Evercore Shagun Singh - RBC Ryan Zimmerman - BTIG Vik Chopra - Wells Fargo Matt Miksic - Barclays Pito Chickering - Deutsche Bank Steven Lichtman - Oppenheimer Drew Ranieri - Morgan Stanley Michael Matson - Needham & Company Joanne Wuensch - Citi Eric Anderson - Cowen Eric Fleming - Raymond James Operator Welcome to the Fourth Quarter and Full Year 2022 Stryker Earnings Call. My name is Tanya, and I will be your operator for today's call.

Stryker Corporation (SYK) Q4 2022 Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of 5.63% and 5.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q4 Earnings and Revenues Top Estimates

Kalamazoo, Michigan , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2022:

Stryker reports 2022 operating results and 2023 outlook

Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Stryker (SYK)

Gilead Sciences

Humana

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its equity portfolio for the fourth quarter of 2022 earlier this week.

Eaton Vance Worldwide Health Sciences Fund Adds 3 Stocks to Portfolio

Stryker is a major medical device company that continues to flesh out its business by targeted acquisitions which, because of its approach, have a strong history of success. The acquisition of Vocera Communications in early 2022 is a clear example of how Stryker makes big changes by acquiring leaders in emerging areas.

Stryker: Excellent Recent And Continuing Performance

Kalamazoo, Michigan, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Tuesday, January 31, 2023 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ending December 31, 2022 and provide an operational update. Final operating results for the quarter will be released at 4:05 p.m. that day.

Stryker to host conference call on January 31, 2023

Agilent Technologies

Ares Commercial Real Estate

American Tower

Andersons

Alexandria Real Estate Equities

Axis Capital

Balchem

Franklin Resources

CubeSmart

Edison

Ensign Group

Four Corners Property Trust

Hingham Institution for Savings

Lincoln Electric Hlds

McCormick

Nucor

Realty Income Corp

Raymond James

ServisFirst Bancshares

Toro

Washington Trust Bancorp

W. P. Carey

York Water

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8% and a median increase of 5.4%.

25 Upcoming Dividend Increases To Finish 2022

Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.

Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries

General Dynamics

New Linde PLC

A way to gain exposure to dividend growers is to invest in a handful of companies across sectors. These are a few of the names research firms like the most.

We Are the Champions: 3 Dividend Growers Wall Street Loves

KALAMAZOO, Mich.--( BUSINESS WIRE )--Stryker (NYSE:SYK) today announced the launch of Citrefix™, a suture anchor system for foot and ankle surgical procedures. The new system uses Citregen™, an award-winning bioresorbable material designed to mimic the chemistry and structure of native bone.1

Stryker launches Citrefix™ Suture Anchor System, featuring award-winning Citregen biomaterial designed to support bone regeneration and the natural healing process

News for Stryker Stock (SYK)